2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
January 2016 in “Hair transplant forum international” The document's content cannot be summarized because it is not accessible or understandable.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
9 citations
,
January 2014 in “DARU Journal of Pharmaceutical Sciences” Cuscuta reflexa extracts helped regrow hair in rats with drug-induced hair loss.
5 citations
,
May 2018 in “Drug Safety” Using electronic health records can help identify drug side effects but has some limitations.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
1 citations
,
November 2024 in “Cureus” Recognizing RSCC is crucial due to its aggressive nature and high risk of poor outcomes.
5 citations
,
December 2014 in “Medicine and Pharmacy Reports” Ciproterone acetate improves hair regrowth and acne in most female patients.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Cuscuta reflexa has potential medicinal benefits but needs more research for clinical use.
April 2019 in “Journal of The American Academy of Dermatology” 56 citations
,
April 2019 in “The Plant Journal” Cyclic nucleotide-gated channels are crucial for proper root hair growth and calcium balance in plants.
November 2020 in “Zenodo (CERN European Organization for Nuclear Research)” 7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
1 citations
,
January 2013 in “International Journal of Trichology” The conference discussed various hair disorders and treatments, including the use of topical steroids, high doses of cetrizine, and hair grafting, as well as the psychological impact of hair loss.
February 2025 in “Cermin Dunia Kedokteran” ADEM is a sudden brain disorder often following infection or vaccination, diagnosed by ruling out other conditions.
1 citations
,
January 2013 Glucosylceramides are essential for healthy skin and proper wound healing.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
30 citations
,
June 2014 in “Seminars in Immunology” Future research on ectodysplasin should explore its role in diseases, stem cells, and evolution, and continue developing treatments for genetic disorders like hypohidrotic ectodermal dysplasia.
3 citations
,
January 1996 in “Journal of Dermatological Treatment” The ointment is a safe, effective, and well-tolerated treatment for certain types of psoriasis.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
November 2025 in “Informatica” The method greatly improves low-light sports images' quality and reduces artifacts.
15 citations
,
October 2016 in “Steroids” Researchers developed a new method to find substances in herbs that can block a specific enzyme linked to hair loss.
PRP shows promise for treating cicatricial alopecia but needs more research.
January 2024 in “Pharmaceutical medicine” Most European physicians know the risks and safe use of Cyproterone acetate, but few remember receiving official safety communications.
November 2022 in “Journal of Investigative Dermatology” DermaCult™ Keratinocyte Expansion Medium allows human skin cells to grow longer while keeping their ability to develop properly.
1 citations
,
September 2023 in “Prostate International” Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.